Duet Or Duel: Will 2019 See More India Pharma Linkages In China?
2018 has seen some interesting Indo-Chinese pharma linkages amid evolving regulations in China and generally improved overall ties between the Asian neighbors. Could the trend stick in 2019 with more Indian firms taking a shot at the world’s second-largest pharma market?
You may also be interested in...
New markets are opening up for Indian firms and China appears to be the flavor of the season, but gaining a strong foothold there is not expected to be even "half as easy" as in the US.
Analysts are enthusiastic about the US earnings prospects of leading Indian generic firm Aurobindo after the company reported a nearly 20% jump in consolidated net profit for the third quarter, and declared it would focus on digesting its acquisitions.
J.P. Morgan Notebook Day 4: US Generics Steady, UroGen, REGENXBIO, Dr. Reddy's In China, And Investor Sentiment Shifts
Daily round-up of news and notes from the 2019 J.P. Morgan Healthcare Conference in San Francisco: US generics see gains, researcher calls for more tech transfer, and biotech investor sentiment rises as big deals bring optimism – among other items from the last day of this year's JPM.